Many patients with autoimmune diseases are excluded from clinical trials of PD-1/PD-L1 inhibitors because of concerns about the activation of underlying autoimmune diseases, the flare of preexisting autoimmune diseases, and the potential susceptibility to severe irAEs. The gene discussed is CD274; the disease is autoimmune disease.